A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data

Statistics in Medicine

Volumn 29, Issue 1, 2010, Pages 75-85

  Saville, Benjamin R ^a   Herring, Amy H ^b,c   Koch, Gary G ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL   (United States)

Author keywords

Composite endpoint structure; Confirmatory clinical trial; Correlated survival and longitudinal data; Nonparametric ANCOVA for logrank scores; Wei Lin Weissfeld

Indexed keywords

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL; TIME; TREATMENT OUTCOME;

AGED; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 74849140646     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3740     Document Type: Article

References (35)

1. Quanjer P. Standardization of lung function testings. Official statement of the European Respiratory Society. European Respiratory Journal 1993; 6:5-40.
2. Laird N, Ware J. Random-effects models for longitudinal data. Biometrics 1982; 38:963-974.
3. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society, Series B 1972; 34:187-220.
4. Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician 2004; 58:16-24.
5. Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics 1997; 53:330-339.
6. Henderson R, Diggle P, Dobson A. Joint modeling of longitudinal measurements and event time data. Biostatistics 2000; 1:465-480.
7. Tsiatis AA, Davidian M. A semiparametric estimator for the proportional hazards model with longitudinal covariates measured with error. Biometrika 2001; 88:447-458.
8. Lin H, Turnbull BW, McCulloch CE, Slate EH. Latent class models for joint analysis of longitudinal biomarker and event process data: application to longitudinal prostate-specific antigen readings and prostate cancer. The American Statistician 2002; 97:53-65.
9. Tseng YK, Hsigh F, Wang JL. Joint modeling of accelerated failure time and longitudinal data. Biometrika 2005; 92:587-603.
10. Elashoff RM, Li G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Statistics in Medicine 2007; 26:2813-2835.
11. Dang QY, Mazumdar S, Anderson SJ, Houck PR, Reynolds CF. Using trajectories from a bivariate growth curve as predictors in a Cox regression model. Statistics in Medicine 2007; 26:800-811.
12. Diggle PJ, Sousa I, Chetwynd AG. Joint modelling of repeated measurements and time-to-event outcomes: the fourth Armitage lecture. Statistics in Medicine 2008; 27:2981-2998.
13. Hogan JW, Laird NM. Model-based approaches to analyzing incomplete longitudinal and failure time data. Statistics in Medicine 1997; 16:259-272.
14. Tsiatis AA, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica 2004; 14:809-834.
15. Yu M, Law NJ, Taylor JMG, Sandler HM. Joint longitudinal-survival-cure models and their application to prostate cancer. Statistica Sinica 2004; 14:835-862.
16. Moye LA, Davis BR, Hawkins CM. Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. Statistics in Medicine 1992; 11:1705-1717.
17. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Statistics in Medicine 1999; 18:1341-1354.
18. Ibrahim JG, Chen MH, Sinha D. Bayesian Survival Analysis. Springer: New York, 2001.
19. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association 1989; 84:1065-1073.
20. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with Discussion). Journal of the Royal Statistical Society, Series B 1972; 34:205-207.
21. Koch GG. Sen PK. Amara IA. Log-rank scores, statistics, and tests. In Encyclopedia of Statistical Sciences, Kotz S, Johnson NL (eds). Wiley: New York, 1985.
22. Tangen CM, Koch GG. Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial. Journal of Biopharmaceutical Statistics 1999; 9:307-338.
23. Tangen CM, Koch GG. Complementary nonparametric analysis of covariance of logistic regression in a randomized clinical trial setting. Journal of Biopharmaceutical Statistics 1999; 9:45-66.
24. Zink RC, Koch GG. SAS macro NParCov version 2, non-parametric analysis of covariance. Biometric Consulting Laboratory, Department of Biostatistics, University of North Carolina at Chapel Hill, 2002.
25. Efron B. The efficiency of Cox's likelihood function for censored data. Journal of the American Statistical Association 1977; 72:557-565.
26. Pauwels R, Buist A, Ma P, Jenkins C, Hurd S. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease: National Heart, Lung, and Blood Institute and World Health Organization global initiative for Chronic Obstructive Lung Disease (GOLD) executive summary. Respiratory Care 2001; 46:798-825.
27. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Controlled Clinical Trials 1997; 18:530-545.
28. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43:487-498.
29. OBrien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-1087.
30. Tang DI, Geller NL, Pocock SJ. On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics 1993; 49:23-30.
31. Koch GG, Tangen CM, Jung JW, Amara IA. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Statistics in Medicine 1998; 17:1863-1892.
32. Guo SW, Lin DY. Regression analysis of multivariate grouped survival data. Biometrics 1994; 50:632-639.
33. Kim MY, Xue X. The analysis of multivariate interval-censored survival data. Statistics in Medicine 2002; 21:3715-3726.
34. Goggins WB, Finkelstein DM. A proportional hazards model for multivariate interval-censored failure time data. Biometrics 2000; 56:940-943.
35. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. The New England Journal of Medicine 2007; 356:775-789.